Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 12;9(2):77.
doi: 10.3390/antibiotics9020077.

In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products

Ming-Jen Sheu  1   2 , Chi-Chung Chen  3   4 , Ying-Chen Lu  3 , Bo-An Su  5 , Chun-Cheng Zhang  5 , Shu-Shen Wang  5 , Yin-Ching Chuang  2   4 , Hung-Jen Tang  5 , Chih-Cheng Lai  6
Affiliations

In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products

Ming-Jen Sheu et al. Antibiotics (Basel). .

Abstract

: This study aims to assess the in vitro activity of different samples of cefoperazone/sulbactam (CFP/SUL) against multidrug-resistant organisms (MDROs). Clinical isolates of extended-spectrum β-lactamase (ESBL)-Escherichia coli, ESBL-Klebsiella pneumoniae, carbapenem-resistant Acinetobacter baumannii (CR-AB), and carbapenem-resistant Pseudomonas aeruginosa (CR-PA) were collected. The minimum inhibitory concentration (MIC) and time-killing methods were used to assess and compare the in vitro activities of different samples of cefoperazone/sulbactam (CFP/SUL) against these MDROs. For ESBL-E. coli, ESBL-K. pneumoniae, and CR-PA, product C had smaller variations than product A and B (p < 0.05). For CR-AB, product B had the largest variation compared to the other two products (p < 0.05). In the time-killing studies, significant differences among the products when used at 16/16 µg/mL were noted for ESBL-E. coli, ESBL-K. pneumoniae, and CR-AB isolates. In conclusion, this study demonstrated the significantly different activity of different products of CFP/SUL against MDROs.

Keywords: antimicrobial activity; cefoperazone/sulbactam; multidrug-resistant organism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
MIC variation in different cefoperazone/sulbactam products against extended-spectrum β-lactamase (ESBL)-E. coli (A), ESBL-K. pneumoniae (B), carbapenem-resistant P. aeruginosa (C), and carbapenem-resistant A. baumannii (D) (* p value < 0.05, ** p value < 0.001, *** p value < 0.0001).
Figure 2
Figure 2
Time-killing study of different cefoperazone/sulbactam products against extended-spectrum β-lactamase (ESBL)-E. coli (A,B), ESBL-K. pneumoniae (C,D), carbapenem-resistant P. aeruginosa (E,F) and carbapenem-resistant A. baumannii (G,H) at the concentrations 16/16 µg/mL and 32/32 µg/mL (* p value < 0.05).
See this image and copyright information in PMC

References

    1. Chiang T.T., Tang T.H., Chiu C.H., Chen T.L., Ho M.W., Lee C.H., Yang Y.-S. Antimicrobial activities of cefoperazone-sulbactam in comparison to cefoperazone against clinical organisms from medical centers in Taiwan. J. Med. Sci. 2016;36:229–233.
    1. Kuo H.-Y., Wang F.-D., Yen Y.-F., Lin M.-L., Liu C.-Y. In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli. New Microbiol. 2009;32:49–55. - PubMed
    1. Pfaller M., Flamm R., Duncan L., Mendes R., Jones R., Sader H. Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014) Diagn. Microbiol. Infect. Dis. 2017;88:177–183. doi: 10.1016/j.diagmicrobio.2017.02.020. - DOI - PubMed
    1. Sidorenko S.V., Rezvan S.P., Tikchonova A.S., Krotova L.A., Ansolis L.E., Tzvigun E.A. In vitro activity of ampicillin, cefoperazone, their combinations with sulbactam and other antimicrobials: Survey of Russian isolates. Int. J. Antimicrob. Agents. 1996;7:109–117. doi: 10.1016/0924-8579(96)00308-1. - DOI - PubMed
    1. Chang P.-C., Chen C.-C., Lu Y.C., Lai C.-C., Huang H.-L., Chuang Y.-C., Tang H.-J. The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms. J. Microbiol. Immunol. Infect. 2018;51:207–213. doi: 10.1016/j.jmii.2017.08.026. - DOI - PubMed

LinkOut - more resources